CVR number 10051428
Industry 46.4620 Wholesale of pharmaceutical goods

MADE FOR MOVEMENT ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  7.8% 5.6% 6.4% 6.2% 4.9%  
Credit score (0-100)  31 39 36 37 44  
Credit rating  BB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  532 1,955 1,684 1,812 1,814  
EBITDA  532 1,276 122 185 135  
EBIT  532 1,272 113 176 130  
Pre-tax profit (PTP)  512.7 1,237.6 72.4 101.9 281.0  
Net earnings  512.7 993.9 55.8 78.6 221.0  
Pre-tax profit without non-rec. items  513 1,238 72.4 102 281  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  0.0 22.4 13.6 4.7 0.0  
Shareholders equity total  252 1,246 1,302 1,381 1,602  
Interest-bearing liabilities  3,644 2,900 4,736 4,347 932  
Balance sheet total (assets)  4,603 5,386 8,119 6,883 3,605  
Net Debt  3,632 2,888 4,724 4,335 932  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  532 1,955 1,684 1,812 1,814  
Gross profit growth  -21.9% 267.8% -13.8% 7.6% 0.1%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  4,603 5,386 8,119 6,883 3,605  
Balance sheet change%  43.3% 17.0% 50.7% -15.2% -47.6%  
Added value  531.6 1,275.8 122.3 185.2 134.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 18 -18 -18 -9  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  2.0 3.0 4.0 5.0 5.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 65.0% 6.7% 9.7% 7.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  13.4% 25.5% 1.7% 5.1% 7.2%  
ROI %  15.8% 31.6% 2.2% 6.5% 9.2%  
ROE %  29.6% 132.6% 4.4% 5.9% 14.8%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  5.5% 23.1% 16.5% 20.4% 44.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  683.3% 226.4% 3,863.4% 2,340.3% 692.6%  
Gearing %  1,443.5% 232.7% 363.7% 314.8% 58.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.9% 1.0% 1.1% 6.2% 3.7%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  1.0 1.2 1.2 1.3 1.7  
Current Ratio  1.1 1.3 1.2 1.3 1.8  
Cash and cash equivalent  12.0 12.0 12.0 12.0 0.0  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  252.5 1,224.5 1,291.6 1,377.1 1,601.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  532 1,276 122 185 135  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  532 1,276 122 185 135  
EBIT / employee  532 1,272 113 176 130  
Net earnings / employee  513 994 56 79 221